SEC Form 4 · accession 0001140361-17-007738
BioRestorative Therapies, Inc. · BRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mandy D. Clyde
Officer — VP of Operations
Period of report
Feb 14, 2017
Accepted (ET)
Feb 15, 2017 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505497
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF9 | $10.00 | Feb 14, 2017 | D | 4,000 | D | Dec 15, 2010 | Dec 14, 2020 | Common Stock | 4,000 | 0 | D |
| Stock OptionF9 | $4.70 | Feb 14, 2017 | A | 4,000 | A | Dec 15, 2010 | Dec 14, 2020 | Common Stock | 4,000 | 4,000 | D |
| Stock OptionF9,F1 | $20.00 | Feb 14, 2017 | D | 300 | D | — | Apr 20, 2021 | Common Stock | 300 | 0 | D |
| Stock OptionF9,F1 | $4.70 | Feb 14, 2017 | A | 300 | A | — | Apr 20, 2021 | Common Stock | 300 | 300 | D |
| Stock OptionF9,F2 | $21.00 | Feb 14, 2017 | D | 1,500 | D | — | Feb 9, 2022 | Common Stock | 1,500 | 0 | D |
| Stock OptionF9,F2 | $4.70 | Feb 14, 2017 | A | 1,500 | A | — | Feb 9, 2022 | Common Stock | 1,500 | 1,500 | D |
| Stock OptionF9,F3 | $30.00 | Feb 14, 2017 | D | 2,500 | D | — | Dec 7, 2022 | Common Stock | 2,500 | 0 | D |
| Stock OptionF9,F3 | $4.70 | Feb 14, 2017 | A | 2,500 | A | — | Dec 7, 2022 | Common Stock | 2,500 | 2,500 | D |
| Stock OptionF9,F4 | $12.00 | Feb 14, 2017 | D | 4,000 | D | — | Oct 4, 2023 | Common Stock | 4,000 | 0 | D |
| Stock OptionF9,F4 | $4.70 | Feb 14, 2017 | A | 4,000 | A | — | Oct 4, 2023 | Common Stock | 4,000 | 4,000 | D |
| Stock OptionF9,F5 | $13.00 | Feb 14, 2017 | D | 6,250 | D | — | Feb 18, 2024 | Common Stock | 6,250 | 0 | D |
| Stock OptionF9,F5 | $4.70 | Feb 14, 2017 | A | 6,250 | A | — | Feb 18, 2024 | Common Stock | 6,250 | 6,250 | D |
| Stock OptionF9,F6 | $6.60 | Feb 14, 2017 | D | 10,000 | D | — | Oct 23, 2024 | Common Stock | 10,000 | 0 | D |
| Stock OptionF9,F6 | $4.70 | Feb 14, 2017 | A | 10,000 | A | — | Oct 23, 2024 | Common Stock | 10,000 | 10,000 | D |
| Stock OptionF9,F7 | $7.00 | Feb 14, 2017 | D | 25,500 | D | — | Sep 4, 2025 | Common Stock | 25,500 | 0 | D |
| Stock OptionF9,F7 | $4.70 | Feb 14, 2017 | A | 25,500 | A | — | Sep 4, 2025 | Common Stock | 25,500 | 25,500 | D |
| Stock OptionF8 | $3.73 | holding | — | — | — | — | Jun 10, 2026 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013.
- F2The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013.
- F3The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013.
- F4The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014.
- F5The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016.
- F6The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017.
- F7The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018.
- F8The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019.
- F9The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.